Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
May 11, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafety Clinical Summary The Drug Enforcement Administration has…
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
May 8, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary This regulatory action places…
Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review.
Comments Off on Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review.
April 7, 2026
Novel psychoactive substances (NPS) represent an evolving public health threat, yet evidence on their acute and long-term psychiatric consequences remains li...